Herpes Simplex Virus-2 glycoprotein D
recombinant, E. coli
Glycoprotein D precursor
For in vitro use only!
Shipping: shipped on blue ice
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Molecular Weight: 65.7 kDa
Purity: > 95 % (SDS-PAGE)
Form: liquid (Supplied in 25 mM Tris-HCl pH 7.2, 1 mM EDTA and 50% glycerol)
The E.coli derived recombinant protein contains the HSV-2 gD immunodominant regions 266-394 amino acids, fused with 26 kDa GST-tag. HSV-2-gD is purified by proprietary chromatographic techniques.
Background: Glycoprotein D (gD) is essential for replication in cultured cells. Deletion mutants of the virus for the gD gene cannot penetrate into cells and neutralizing antibodies against the glycoprotein inhibit virus entry. Studies with antibodies raised against HSV gD indicate that the glycoprotein plays a role in the cell-to-cell fusion process.
Recombinant rHSV-2 gD Antigen may be used in ELISA and Western blots, excellent for detection of HSV with minimal specificity problems.
Specificity: Immunoreactive with sera of HSV-infected individuals.
Domingo et al. (2003) Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D. Vaccine. 21:3565.
Murata et al. (2002) Excretion of herpes simplex virus type 2 glycoprotein D into the culture medium. J. Gen. Virol. 83:2791.
Heineman et al. (1995) Immunization with recombinant varicellazoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J. Virol. 69:8109.
Straus et al. (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 343:1460.
Nakao et al. (1994) Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. J. Infect. Dis. 169:787.
Straus et al. (1993) Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J. Infect. Dis. 167:1045.